Edwards Lifesciences Corporation (EW) shares have surged 21.8% year to date compared with the industry’s rise of 7.2%. The Medical sector has gained 5.2% in the said time frame. The company has a market capitalization of $55.83 billion.The company’s consistent growth performance reflects its commitment to advancing its leadership in surgical structural heart therapies. The strategic spin-off of Critical Care aims to boost the company’s R&D and innovations and enable a sharpened focus on structural heart dis ...

PITTSBURGH--(BUSINESS WIRE)--PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last, has received an additional CE Mark for its exGraft family of vascular grafts, expanding its on-label use. exGraft vascular grafts are intended for use as vascular prostheses for replacement or bypass of diseased or injured vessels, and with the new clearance, exGraft now includes instructions for post-operative exp ...

Shares of Edwards Lifesciences (EW) reached a new 52-week high of $95.27 on Mar 14, 2024, before closing the session marginally lower at $93.36.In the past year, this Zacks Rank #2 (Buy) stock has gained 13.9% compared with the 11.5% rise of the industry and the S&P 500 composite’s rise of 30.2%.Over the past five years, Edwards Lifesciences registered earnings growth of 9.9% compared with the industry’s 8.5% rise. The company’s expected 2024 earnings growth rate of 9.9% compares favorably with the industry ...

Edwards Lifesciences, Inc. (EW) presented results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform. The data were published in the Journal of the American College of Cardiology (JACC), Cardiovascular Interventions.The recent development will strengthen Edwards Lifesciences transcatheter aortic valve replacement (TAVR) and surgical structural heart business.Study DetailsIn a study of real-w ...

WASHINGTON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform. A study of Edwards’ latest TAVR technology, the SAPIEN 3 Ultra RESILIA valve, found lower rates of paravalvular leak (PVL) at 30 days, lower echo-derived gradients and larger effective orifi ...

Edwards Lifesciences (EW) has been gaining from strength across all key segments. Innovation also aids growth. The stock carries a Zacks Rank #2 (Buy) currently.Edwards’ Surgical Structural Heart business pioneered the innovative RESILIA tissue, which is backed by more than 40 years of the company’s tissue technology leadership. The RESILIA portfolio has been widely adopted because of the excellent durability of its proven tissue technology. The company is optimistic about the future of this technology as i ...

Investors interested in Medical - Instruments stocks are likely familiar with Hologic (HOLX) and Edwards Lifesciences (EW) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate ...

Edwards Lifesciences Corporation (EW) is gaining from its commitment to advance its leadership position in surgical structural heart therapies. The SAPIEN 3 Ultra RESILIA platform also continues its strong uptake in the United States.Elevated expenses and foreign exchange headwinds are a concern for EW’s business.In the past year, this Zacks Rank #2 (Buy) stock has gained 13.4% compared with 11.2% rise of the industry and 30.8% growth of the S&P 500 composite.The renowned global medical device company has a ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edward ...

Edwards Lifesciences (EW) is benefiting from strength across all product groups. The company’s bullish long-term growth strategy buoys optimism on the stock. The stock currently carries a Zacks Rank #2 (Buy).In December 2023, Edwards announced the strategic decision to spin off the Critical Care segment at the end of 2024. The company expects this tax-free, planned separation to act strategically to its core business. With this spin-off, the company pursues more opportunities for Transcatheter Aortic Valve ...